Bio-Rad Laboratories, Inc. (BIO) shares rose 1.6% to $366.16 as of October 10, 2026, a modest gain from the prior close of $360.40. BestStocks flagged the session as a major change for BIO. The move is tied to company news. Below, we break down what changed for BIO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 Globe Newswire reports on BIO.
This summary describes the catalyst and move as first detected on Oct 5, 2026, 10:19 AM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
0.5×
Below Avg
Vs peers
—
No comparable peers
Market cap
$9.9B
New York Stock Exchange
Analyst target
$350
-4.4% vs price
Price chart
Sep 9 – Oct 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Bio-Rad Laboratories, Inc. investors
For Bio-Rad Laboratories, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 1.6% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $350.00, implying -4.4% downside from $366.16. BestStocks rates the overall signal quality weak (37/100). With earnings roughly 19 days out, the next report is the most likely near-term test of the move.
BIO price reaction
BIO last traded at $366.16, up $5.76 (+1.60%) from the previous close of $360.40. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $355.57 and $387.54, and it currently sits about 33% of the way up that band.
Bullish and bearish analyst opinions on Bio-Rad Laboratories, Inc. (BIO)
The consensus analyst price target on Bio-Rad Laboratories, Inc. (BIO) is $350.00, 4.4% below the recent $366.16. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BIO line up.
▲ The bullish case
+The Street's most bullish target is $390.00 (+6.5%).
+Material positive event.
+Positive 1.6% session move.
+Bio-Rad Laboratories, Inc. (BIO) moved +3.92% from $339.18 to $352.47 on 2026-08-07, reaching a new 30-day high.
▼ The bearish case
−The consensus analyst price target of $350.00 sits 4.4% below the recent $366.16, so the average target sees limited room to run.
−The most bearish analyst target is $310.00 (-15.3%).
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Bio-Rad Laboratories, Inc. (BIO) moved −3.27% from $372.59 to $360.40 on 2026-10-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.3× the 5-day average, suggesting modest institutional interest in the decline.
Material / Earnings2026-10-06-2.9%
Bio-Rad Laboratories, Inc. (BIO) moved -3.80% from $383.38 to $368.83 on 2026-10-06. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the decline occurred on typical trading activity.
Material / Earnings2026-10-05+2.9%
Bio-Rad Laboratories, Inc. (BIO) moved +3.19% from $368.07 to $379.82 on 2026-10-05 following news that PDAOAI opened a BIO REBOOT collaboration and showcased Partitioned Literature Aggregation at Drug Discovery 2026.
Material / Earnings2026-10-02+3.8%
Bio-Rad Laboratories, Inc. (BIO) moved +3.32% from $357.28 to $369.14 on 2026-10-02. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-10-01-5.9%
Bio-Rad Laboratories, Inc. (BIO) moved -4.89% from $373.87 to $355.57 on 2026-10-01. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move coincided with BIO reaching a new 30-day low, while volume remained near its 5-day average.
Material / Earnings2026-09-24+2.3%
BIO moved +2.60% from its $377.73 open to a $387.54 close on 2026-09-24.
Material / Earnings2026-09-15+2.6%
Bio-Rad Laboratories, Inc. (BIO) moved +3.19% from $366.33 to $378.00 on 2026-09-15. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on elevated volume (2.0x the 5-day average), suggesting institutional interest, but the driver remains unclear.
Material / Earnings2026-09-10-2.2%
Bio-Rad Laboratories, Inc. (BIO) moved -3.47% from $382.01 to $368.75 on 2026-09-10. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.9x the 5-day average, modestly elevated.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 19 days
10-Q Filing (est.)
2026-11-03
Medium impact
Thesis shift
Bullish Shift
bullish signal
Risk level
Low
from change events
Frequently asked questions about BIO
Why did Bio-Rad Laboratories, Inc. (BIO) stock move?
BIO rose 1.6% to $366.16. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did BIO stock rise?
BIO gained 1.60% ($5.76) versus the prior close of $360.40, last trading at $366.16 on 0.5× average volume.
When is Bio-Rad Laboratories, Inc.'s next earnings date?
BIO's next earnings report is estimated for 2026-10-29 — about 19 days away.
What is the analyst price target for BIO?
The consensus analyst price target for BIO is $350.00, about 4.4% below the current $366.16. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks BIO
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for BIO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
